Evidence for non-communicable diseases: analysis of Cochrane reviews and randomised trials by World Bank classification

Abstract

IntroductionPrevalence of non-communicable diseases (NCDs) is increasing globally, with the greatest projected increases in low-income and middle-income countries. We sought to quantify the proportion of Cochrane evidence relating to NCDs derived from such countries.MethodsWe searched the Cochrane database of systematic reviews for reviews relating to NCDs highlighted in the WHO NCD action plan (cardiovascular, cancers, diabetes and chronic respiratory diseases). We excluded reviews at the protocol stage and those that were repeated or had been withdrawn. For each review, two independent researchers extracted data relating to the country of the corresponding author and the number of trials and participants from countries, using the World Bank classification of gross national income per capita.Results797 reviews were analysed, with a reported total number of 12 340 trials and 10 937 306 participants. Of the corresponding authors 90% were from high-income countries (41% from the UK). Of the 746 reviews in which at least one trial had met the inclusion criteria, only 55% provided a summary of the country of included trials. Analysis of the 633 reviews in which country of trials could be established revealed that almost 90% of trials and over 80% of participants were from high-income countries. 438 (5%) trials including 1 145 013 (11.7%) participants were undertaken in low-middle income countries. We found that only 13 (0.15%) trials with 982 (0.01%) participants were undertaken in low-income countries. Other than the five Cochrane NCD corresponding authors from South Africa, only one other corresponding author was from Africa (Gambia).DiscussionThe overwhelming body of evidence for NCDs pertains to high-income countries, with only a small number of review authors based in low-income settings. As a consequence, there is an urgent need for research infrastructure and funding for the undertaking of high-quality trials in this area.

Integration of HIV/AIDS and noncommunicable diseases in developing countries: rationale, policies and models

“…A recent study about evidence for NCDs indicated that the overwhelming body of evidence for NCDs is from developed countries. [4] Integration with HIV could pave the way for NCD response to learn from HIV responses. In this regard, there are some disease and service specific attempts to integrate NCD services in to HIV/AIDS programs in developing countries.…”

Health system barriers and facilitators to medication adherence for the secondary prevention of cardiovascular disease: A systematic review

“…9 42 However, a recent analysis of Cochrane reviews and RCTs in non-communicable diseases (including CVD) showed that almost 90% of trials and over 80% of participants were from high-income countries, 43 and our analysis further highlights the sparse data for policymakers to make evidence-based changes to improve adherence to secondary prevention medications for CVD, particularly in low-income settings. The overall quality of evidence is low by objective criteria, 44 due to lack of directness of evidence, heterogeneity across studies and only 12 (48%) of the 25 included studies being RCTs.…”

Setting up a clinical trial for a novel disease: a case study of the Doxycycline for the Treatment of Nodding Syndrome Trial – challenges, enablers and lessons learned

“…Experiences from the increasing number of clinical trials conducted in low-income countries is seldom reported [5,6]. The complexity of implementing trials includes lengthy procedures for study approval, regulatory processes and community engagement needs, which make trial set-up labour-intensive and costly [7].…”